Figure 2.
α1-Antitrypsin variants SMTR/S and SLLR/S target thrombin, FXa, and APC. (A-B,F) Inhibition of enzymes at a fixed SERPIN concentration; table insets show second-order rate constants (k2: 104 M−1·s−1). (A) Inhibition of 17.7 nM thrombin by 38.5 nM SERPIN. (B) Inhibition of 8.5 nM FXa by 192.3 nM SERPIN. (C) Inhibition of dilute PT clotting times in normal plasma in the presence of SERPINs. (D-E) Inhibition of TF-driven thrombin generation in the presence of 384 nM SERPIN. (F) Inhibition of 17.9 nM APC by 96.2 nM SERPIN. (G) Inhibition of APC by 384 nM SERPIN in an aPTT clotting assay. Data are expressed as a ratio of the APC-dependent increase in clotting times. Data represent the mean ± SD of 3 separate experiments, each performed in duplicate. #P < .005; †P < .0005; §P < .0001, compared with pdC1INH by 1-way ANOVA.

α1-Antitrypsin variants SMTR/S and SLLR/S target thrombin, FXa, and APC. (A-B,F) Inhibition of enzymes at a fixed SERPIN concentration; table insets show second-order rate constants (k2: 104 M−1·s−1). (A) Inhibition of 17.7 nM thrombin by 38.5 nM SERPIN. (B) Inhibition of 8.5 nM FXa by 192.3 nM SERPIN. (C) Inhibition of dilute PT clotting times in normal plasma in the presence of SERPINs. (D-E) Inhibition of TF-driven thrombin generation in the presence of 384 nM SERPIN. (F) Inhibition of 17.9 nM APC by 96.2 nM SERPIN. (G) Inhibition of APC by 384 nM SERPIN in an aPTT clotting assay. Data are expressed as a ratio of the APC-dependent increase in clotting times. Data represent the mean ± SD of 3 separate experiments, each performed in duplicate. #P < .005; †P < .0005; §P < .0001, compared with pdC1INH by 1-way ANOVA.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal